| Chanida Putwanphen Wilson, | |
|
1100 7th Ave Sw, Albany, OR 97321-1925 | |
| (541) 812-5600 | |
| Not Available |
| Full Name | Chanida Putwanphen Wilson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 1100 7th Ave Sw, Albany, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376279323 | NPI | - | NPPES |
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20031111000297 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
| Entity Name | Good Samaritan Hospital Corvallis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453134 PECOS PAC ID: 1557270725 Enrollment ID: O20031125000163 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20040120000329 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174888010 PECOS PAC ID: 2466353529 Enrollment ID: O20040204000304 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
| Entity Name | Albany General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154372340 PECOS PAC ID: 9931097987 Enrollment ID: O20040310000310 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20061104000117 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20061104000140 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1801847066 PECOS PAC ID: 2466353529 Enrollment ID: O20061104000163 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chanida Putwanphen Wilson, Po Box 1189, Corvallis, OR 97339-1189 Ph: () - | Chanida Putwanphen Wilson, 1100 7th Ave Sw, Albany, OR 97321-1925 Ph: (541) 812-5600 |
News Archive
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.
The Democratic National Committee on Monday during the Democratic National Convention voted to adopt a non-binding party platform that includes language about health care, the AP/Long Island Newsday reports. According to the AP/Newsday, the platform in large part follows recommendations from presumptive Democratic presidential nominee Sen. Barack Obama (Ill.) but moves "beyond his proposals in calling for guaranteed health care for all" (Woodward, AP/Long Island Newsday, 8/26).
Niusule Biotech Corp., a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced revenue, gross margin, and net income guidance for calendar year ending December 31, 2010 ("CY 2010").
› Verified 8 days ago
Huei Ling Tsai, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2832 Weather Stone St Nw # Na, Albany, OR 97321 Phone: 415-619-4332 | |
Ms. Virginia J Taylor, CFNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1100 7th Ave Sw, Albany, OR 97321 Phone: 541-812-4980 Fax: 541-926-9329 | |
Mrs. Jessica Anne Henry, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1700 Geary St Se, Albany, OR 97322 Phone: 541-812-5500 | |
Ms. Jennifer Marie Wilson, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1700 Geary St Se, Albany, OR 97322 Phone: 541-812-5500 | |
Susan Parker, RN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1005 Springhill Dr. Nw, Albany, OR 97321 Phone: 541-967-4518 | |
Mrs. Yvonne Elaine Keep, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1705 Waverly Dr Se, Albany, OR 97322 Phone: 541-967-8221 | |
Jonell Blase, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1100 7th Ave Sw, Albany, OR 97321 Phone: 541-812-5600 |